© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Peggy Peck
Articles
FDA Warns of Sedative-Aided Sleep Driving and Anaphylaxis
March 14, 2007
ROCKVILLE, Md -- The FDA has taken steps to ensure that clinicians and patients are aware of rare bizarre effects associated with sedative hypnotics, including driving or eating while sleeping.
FDA Okays Lapatinib (Tykerb) for Treatment-Resistant Breast Cancer
March 13, 2007
ROCKVILLE, Md. -- The FDA today approved lapatinib (Tykerb), an oral kinase inhibitor that targets HER2-positive tumors, for treatment-refractory metastatic breast cancer, to be used in combination with capectabine (Xeloda).
Pioglitazone (Actos) Increases Limb Fractures in Women
March 09, 2007
ROCKVILLE, Md. -- For the second time in two weeks, the FDA has informed physicians of an excess fracture risk in women taking an oral diabetes drug in the thiazolidinedione class. This time the drug is pioglitazone (Actos).
Low-Battery Glitch Forces Recall of 42,000 Automatic External Defibrillators
March 08, 2007
ROCKVILLE, Md. -- More than 40,000 automatic external defibrillators in schools, health clubs, and other public sites have been recalled because of a potentially faulty low-battery signal, the FDA reported.
FDA Okays First Direct Renin Inhibitor for Hypertension
March 06, 2007
ROCKVILLE, Md. -- The FDA said today it has approved aliskiren (Tektuma), the first oral direct renin inhibitor for treatment of hypertension.
FDA Okays Gene Test to Screen Donor Blood for West Nile
March 05, 2007
ROCKVILLE, Md. -- The FDA has licensed an automated nucleic acid test to screen donor blood for West Nile virus.
FDA Cites Norovirus in Raw Oysters in South Texas Gulf
March 05, 2007
ROCKVILLE, Md. -- The FDA has warned about a norovirus outbreak linked to raw oysters harvested in San Antonio Bay, on the Texas Gulf coast north of Corpus Christi.
ADHD Drug Designed to Limit Abuse Wins FDA Okay
February 27, 2007
ROCKVILLE, Md. -- The FDA has approved lisdexamfetamine dimesylate (Vyvanse), formerly known as NRP104, for attention deficit hyperactivity disorder.
ASCO PROSTATE: More Radiation Improves PSA Control but Increases Toxicities
February 26, 2007
KISSISSIMEE, FLA. -- Escalated-dose conformal radiotherapy for localized prostate cancer was associated with a 34% reduction in the relative risk of biochemical failure in a randomized trial of 843 men also with treated with androgen deprivation therapy.
FDA Orders Black Box Anaphylaxis Warning for Omalizumab (Xolair)
February 21, 2007
ROCKVILLE, Md. -- Anaphylaxis reports associated with the asthma drug omalizumab (Xolair) led the FDA today to order Genentech to add a black box warning to the agent's label.